Meriofert Pfs

Luteinising Hormone (Human) and Follicle‑Stimulating Hormone, the active ingredients in Meriofert Pfs, are gonadotropins presented as an injectable preparation for intramuscular, subcutaneous use. It stimulates gonadal steroidogenesis and gametogenesis in individuals with reproductive hormone deficiencies.

GNH USA supplies Meriofert Pfs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert Pfs contains human luteinising hormone and follicle‑stimulating hormone and is used in reproductive hormone therapy.

- Ovulation induction: supports follicular development and triggers ovulation in women with anovulation. - Controlled ovarian stimulation: enhances follicular response in assisted reproductive technology cycles. - Male hypogonadotropic hypogonadism: stimulates spermatogenesis in men with deficient gonadotropins.

Adverse reactions may occur following administration of Meriofert Pfs.

Common Side Effects: - Injection site pain or erythema: mild local discomfort at the injection site. - Headache: transient headache reported in some patients. - Abdominal discomfort: mild stomach upset or cramping. - Nausea: occasional feeling of nausea after dosing. - Mild ovarian hyperstimulation: limited follicular response without severe complications.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome: severe fluid shift and abdominal distension. - Multiple pregnancy: increased risk of twins or higher order gestations. - Thromboembolic events: rare clot formation requiring immediate attention. - Allergic reaction: rash, urticaria, or anaphylaxis. - Ectopic pregnancy: rare implantation outside the uterus. - Severe abdominal pain: may indicate complications such as ovarian torsion.

Careful assessment and monitoring are required when using Meriofert Pfs.

- Pregnancy: avoid unless prescribed by a fertility specialist, as safety data are limited. - Breastfeeding: use with caution; potential effects on milk production are unknown. - Ovarian response: monitor follicular development to prevent excessive stimulation. - Hormone‑dependent tumors: contraindicated in patients with known estrogen‑sensitive neoplasms. - Specialist supervision: administration should be overseen by qualified reproductive endocrinologists. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be evaluated before initiating therapy.

Major Interactions (Avoid): - Hormonal contraceptives: may antagonize the intended gonadotropin effect. - Other gonadotropins: additive stimulation can precipitate severe ovarian hyperstimulation.

Moderate Interactions (Monitor Closely): - GnRH agonists or antagonists: may alter the pharmacodynamic response. - Corticosteroids: can affect hormone metabolism and response. - Anticoagulants: monitor for clotting abnormalities if ovarian hyperstimulation occurs. - Thyroid hormone therapy: adjust dosing as thyroid status influences gonadotropin activity.